A study on drug safety monitoring program in India

Indian Journal of Pharmaceutical Sciences

Volumn 76, Issue 5, 2014, Pages 379-386

  Ahmad, A ^a   Patel, Isha ^b   Sanyal, Sudeepa ^c   Balkrishnan, R ^b   Mohanta, G P ^a  

^a ANNAMALAI UNIVERSITY   (India)

^b UNIVERSITY OF MICHIGAN   (United States)

^c Walmart Pharmacy   (United States)

Author keywords

Adverse drug reaction; banned drugs; drug safety; pharmacovigilance

Indexed keywords

ASTEMIZOLE; CISAPRIDE; CLIOQUINOL; DICLOFENAC; DIPYRONE; DROPERIDOL; FURAZOLIDONE; GATIFLOXACIN; LETROZOLE; NIMESULIDE; NITROFURAL; OXYPHENBUTAZONE; PHENFORMIN; PHENOLPHTHALEIN; PHENYLPROPANOLAMINE; PIPERAZINE; RIMONABANT; ROFECOXIB; ROSIGLITAZONE; SIBUTRAMINE; TEGASEROD; VALDECOXIB;

CLINICAL PRACTICE; CONSUMER; DEVELOPED COUNTRY; DRUG EFFICACY; DRUG MARKETING; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; GOLD STANDARD; HUMAN; INDIA; PHARMACIST; REVIEW; UNITED KINGDOM; UNITED STATES;

EID: 84908403188     PISSN: 0250474X     EISSN: 19983743     Source Type: Journal    
DOI: None     Document Type: Review

References (35)

1. Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients: A meta-analysis of prospective studies. JAMA 1998;279:1200-5.
2. World Health Organization. Safety of Medicines. A guide to detecting and reporting adverse drug reactions. Geneva, Switzerland: WHO 2002. Available from: http://www.whqlibdoc.who.int/hq/2002/WHO-EDM- QSM-2002.2.pdf [Last accessed on 2012 Oct 31].
3. Moore N, Lecointre D, Noblet C, Mabille M. Frequency and cost of serious adverse drug reactions in a department of general medicine. Br J Clin Pharmacol 1998;45:301-8.
4. Ramesh M, Pandit J, Parthasarathi G. Adverse drug reactions in a south Indian hospital-their severity and cost involved. Pharmacoepidemiol Drug Saf 2003;12:687-92.
5. Arulmani R, Rajendran SD, Suresh B. Adverse drug reaction monitoring in a secondary care hospital in South India. Br J Clin Pharmacol 2008;65:210-6.
6. Ahmad A, Parimalakrishnan S, Mohanta GP, Manna PK, Manavalan R. Incidence of adverse drug reactions with commonly prescribed drugs in tertiary care teaching hospital in India. Int J Pharm Sci 2011;3:79-83.
7. Ahmad A, Patel I, Balkrishnan R, Mohanta GP, Manna PK. An evaluation of knowledge, attitude and practice of Indian pharmacists towards adverse drug reaction reporting: A pilot study. Perspect Clin Res 2013;4:204-10.
8. Rawlins MD. Spontaneous reporting of adverse drug reactions. Br J Clin Pharmacol 1988;26:1-5.
9. Dukes MN. The importance of adverse reactions in drug regulation. Drug Saf 1990;5:3-6.
10. Tripathi KD. Essentials of medical pharmacology. 6th ed. New Delhi: Jaypee Brothers Medical Publishers Pvt. Ltd.; 2008. p. 129-692.
11. Drugs banned in the Country. Available from: http://www.cdsco.nic. in/writereaddata/drugs%20banned%20in%20thed%20country.pdf [Last accessed on 2012 Oct 5].
12. Park-Wyllie LY, Juurlink DN, Kopp A, Shah BR, Stukel TA, Stumpo C et al. Outpatient gatifloxacin therapy and dysglycemia in olderadults. N Engl J Med 2006;354:1352-61.
13. Gurwitz JH. Serious adverse drug effects-seeing the trees through the forest. N Engl J Med 2006;354:1413-5.
14. "Two drugs banned". The Hindu (Chennai, India). Available from: http://www.thehindu.com/news/national/article1551233.ece. [Last accessed on 2012 Jul 5].
15. Lazarus D. Avandia: When does a drug's harm outweigh its benefit- Los Angels Times. 2010 Jul 1. Available from: http://www.articles. latimes.com/2010/jul/01/business/la-fi-lazarus-20100702. [Last accessed on 2012 Oct 5].
16. After ban in India, docs warn diabetics of rosiglitazone use. Available from: http://www.indianexpress.com/news/after-ban-in-india-docs-warndiabetics-of-r/694755/[Last accessed on 2012 Oct 31].
17. The Times of India. Ban on Tegaserod, Gatifloxacine due to sideeffects. New Delhi. 2011, Available from: http://www.articles. timesofindia.indiatimes.com/2011-03-19/india/29146073-1-dipblood-sugar-levels-gatifloxacine-tegaserod. [Last accessed on 2012 Jun 29].
18. India today. Government bans nimesulide banned over adverse effects on liver. New Delhi. Available from: http://www.indiatoday.intoday. in/story/government-bans-nimesulide/1/129859.html [Last accessed on 2012 Sep 5].
19. Rahman SZ, Khan RA. Is nimesulide safe in a cardiovascular-Compromised patient- Indian J Pharmacol 2004;36:252-3.
20. Khan RA, Rahman SZ. A case report on Nimesulide and its relation with angina. J Pharmacovigilance Drug Saf 2004;1:19-21.
21. Slimming drug Sibutramine banned in India. Available from: http:// www.indianexpress.com/news/slimming-drug-sibutramine-banned-in India/710526 [Last accessed on 2012 Oct 5].
22. Use of pain-killer Rofecoxib banned. Available from: http://www. hindu.com/2004/10/13/stories/2004101306241200.htm [Last accessed on 2012 Jun 28].
23. U.S. Food and Drug Administration, Bextra (valdecoxib) Apr 2005. Available from: http://www.fda.gov/Safety/MedWatch/SafetyInformation/ SafetyAlertsforHumanMedicalProducts/ucm150752.htm [Last accessed on 2012 Oct 31].
24. Dance with shadows. India bans valdecoxib. Available from: http:// www.dancewithshadows.com/hara/india-ban-valdecoxib.asp [Last accessed on 2012 Oct 31].
25. Finally, expert panel bans fertility drug Letrozole. Available from: http:// www.articles.timesofindia.indiatimes.com/2011-10-18/india/30296687-1- letrozole-breast-cancer-post-menopausal-women [Last accessed on 2012 Oct 31].
26. Government may ban antiobesity drug Rimonabant, Available from: http://www.business-standard.com/india/news/govt-may-ban-anti-obesitydrug-rimonabant/343972/[Last accessed on 2012 Oct 31].
27. Drugs Banned in other Countries But Available in India. Available from: http://www.medindia.net/patients/patientinfo/drugs-bannedin-other-countries-but-available-in-india.htm [Last accessed on 2012 Oct 31].
28. Pharmacovigilance in UK. Available from: http://www.liv. ac.uk/pharmacovigilance/pages/pharmuk.htm. [Last accessed on 2012 Oct 31].
29. United States FDA. FDA issues final risk minimization guidance. Available from: http://www.fda.gov/bbs/topics/news/2005. [Last accessed on 2012 Oct 31].
30. FDA. Premarketing risk assessment guidance. Available from: http:// www.fda.gov/cder/guidance [Last accessed on 2012 Oct 31].
31. FDA. Development and use of risk minimization action plans. Available from: http://www.fda.gov/cder/guidance [Last accessed on 2012 Oct 31].
32. Pharmacovigilance Programme of India for assuring drug safety. Available from: http://www.cdsco.nic.in/pharmacovigilance.htm. [Last accessed on 2012 Oct 29].
33. Sreeraman Sub-committee Formed to Check the Circulation of Banned Drugs in India. Available from: http://www.medindia.net/ news/Sub-committee-Formed-to-Check-the-Circulation-of-Banned-Drugs-in-India-25795-1.htm. [Last accessed on 2012 Oct 31].
34. Amrita P, Kharbanda B. Knowledge, Attitude and Skills of nurses of Delhi towards adverse drug reaction reporting. Indian J Pharm Pract 2012;5:45-51.
35. Srikanth BA, Ahmad A, Reddy KR, Balkrishnan R, Nagappa NA, Acceptance of doctor of pharmacy in India: A survey based study, Arc Pharm Prac 2013;4:93-7.